Spots Global Cancer Trial Database for myeloid
Every month we try and update this database with for myeloid cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations | NCT01522469 | Relapsed or Ref... | Crenolanib Besy... | 18 Years - | Arog Pharmaceuticals, Inc. | |
| Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents | NCT00111345 | Myeloid Leukemi... | Anthracyclines liposomal dauno... 2-CDA AI | 1 Day - 18 Years | University Hospital Muenster | |
| Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia | NCT00607997 | Leukemia Acute Disease Acute Myeloid L... Nonlymphocytic ... Myelodysplastic... | vosaroxin | 60 Years - | Sunesis Pharmaceuticals | |
| GRASPA Treatment for Patients With Acute Myeloblastic Leukemia | NCT01810705 | Acute Myeloid L... | GRASPA | 65 Years - 85 Years | ERYtech Pharma | |
| A Clinical Research of CD123-Targeted CAR-T in Myeloid Malignancies | NCT02937103 | Leukemia | Anti-CD123-CAR-... | 14 Years - 75 Years | Southwest Hospital, China | |
| Beat AML Core Study | NCT02927106 | Acute Myeloid L... | 18 Years - 80 Years | University of Florida | ||
| Immunotherapy Using Lenalidomide + Bystander Vaccine in High Risk Myelodysplastic Syndrome (MDS) | NCT00840931 | Leukemia | lenalidomide bystander vacci... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Efficacy and Toxicity of Increasing Doses of Idarubicin, Cytarabine and G-CSF in Acute Myeloid Leukemia | NCT01700413 | Di Novo Acute M... | Idarubicin | 18 Years - 70 Years | Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias | |
| A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms | NCT04955938 | IDH Mutation IDH1 Mutation IDH2 Gene Mutat... Blood Cancer Myeloproliferat... | Ivosidenib Enasidenib Fedratinib | 18 Years - | University of Chicago | |
| In Vitro Drug Sensitivity Testing of Fresh Human Samples | NCT05001386 | Myeloproliferat... Lymphoprolifera... | Blood collectio... | 18 Years - | Hospices Civils de Lyon | |
| Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia | NCT01460693 | Myeloid Leukemi... | Imatinib Dasatinib | 18 Years - | Newcastle University | |
| AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen | NCT01018069 | Leukemia | AEG35156 | 18 Years - | Aegera Therapeutics | |
| Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia | NCT01743859 | Acute Myeloid L... | Azacitidine Lenalidomide Off Therapy | 18 Years - | University of Colorado, Denver | |
| Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias | NCT00261846 | Chronic Myeloid... | Bosutinib | 18 Years - | Pfizer | |
| Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML) | NCT00822094 | Acute Myeloid L... | CPX-351 Intensive Salva... | 18 Years - 65 Years | Jazz Pharmaceuticals | |
| Risk-adapted Therapy for Primary Acute Myeloid Leukemia | NCT04687098 | Leukemia, Myelo... | Idarubicin Ara-C G-CSF Allogeneic matc... Autologous peri... Measurable resi... | 17 Years - 70 Years | Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias | |
| Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy | NCT04090736 | Leukemia, Myelo... | Pevonedistat Azacitidine | 18 Years - | PETHEMA Foundation | |
| Evaluation of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia | NCT00478985 | Myeloid Leukemi... | Imatinib ending | 18 Years - | University Hospital, Bordeaux | |
| Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias | NCT00261846 | Chronic Myeloid... | Bosutinib | 18 Years - | Pfizer | |
| Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia | NCT00037583 | Acute Myeloid L... | Gemtuzumab Ozog... | 18 Years - 59 Years | Wyeth is now a wholly owned subsidiary of Pfizer | |
| Efficacy and Toxicity of Increasing Doses of Idarubicin, Cytarabine and G-CSF in Acute Myeloid Leukemia | NCT01700413 | Di Novo Acute M... | Idarubicin | 18 Years - 70 Years | Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias | |
| Study Protocol: Study on Incidence and Risk Factors of Mold Infections in Children During Leukemia Treatment | NCT05774990 | Leukemia, Myelo... Acute Lymphobla... | - 17 Years | University of Southern Denmark | ||
| Lentivirally Redirected CD123 Autologous T Cells in AML | NCT03766126 | Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... | CART123 cells; ... | 18 Years - | University of Pennsylvania | |
| Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukaemia in Long Term After Stopping Imatinib | NCT01343173 | Chronic Myeloid... | Imatinib stop | 18 Years - | University Hospital, Bordeaux | |
| An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML) | NCT03114228 | FLT3-mutated Ac... | Midostaurin | 18 Years - | Novartis | |
| A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations | NCT02381886 | Advanced Malign... | IDH305 | 18 Years - | Novartis | |
| A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms | NCT04955938 | IDH Mutation IDH1 Mutation IDH2 Gene Mutat... Blood Cancer Myeloproliferat... | Ivosidenib Enasidenib Fedratinib | 18 Years - | University of Chicago | |
| CD123 Redirected T Cells for AML in Pediatric Subjects | NCT04678336 | Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... | CART123 cells; ... | 1 Year - 29 Years | University of Pennsylvania | |
| Beat AML Core Study | NCT02927106 | Acute Myeloid L... | 18 Years - 80 Years | University of Florida | ||
| Natural Killer (NK) Cell Transplantation for AML | NCT00187096 | Acute Myeloid L... | Cyclophosphamid... Natural Killer ... CliniMACS Syste... | - 21 Years | St. Jude Children's Research Hospital | |
| Natural Killer (NK) Cell Transplantation for AML | NCT00187096 | Acute Myeloid L... | Cyclophosphamid... Natural Killer ... CliniMACS Syste... | - 21 Years | St. Jude Children's Research Hospital | |
| Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy | NCT04090736 | Leukemia, Myelo... | Pevonedistat Azacitidine | 18 Years - | PETHEMA Foundation | |
| Comparing Two Diets in Patients Undergoing HSCT or Remission Induction Chemo for Acute Leukemia and MDS (UF-BMT-LDND-101) | NCT03016130 | Leukemia Myelodysplastic... | Diet | 18 Years - | University of Florida | |
| First-in-Human Safety, Tolerability and Antitumour Activity Study of MTL-CEBPA in Patients With Advanced Liver Cancer | NCT02716012 | Hepatocellular ... Liver Cancer | MTL-CEBPA Sorafenib 200mg | 16 Years - | Mina Alpha Limited | |
| CD123 Redirected T Cells for AML in Pediatric Subjects | NCT04678336 | Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... | CART123 cells; ... | 1 Year - 29 Years | University of Pennsylvania | |
| A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome. | NCT01236144 | Acute Myeloid L... High Risk Myelo... | Plerixafor AC220 Ganetespib | 60 Years - | Cardiff University | |
| Risk Adapted Treatment for Primary Acute Myeloid Leukemia (AML) | NCT01723657 | Leukemia, Myelo... | Ara-C Autologous peri... Allogeneic matc... G-CSF CD34+ selection... Mylotarg purgin... | 18 Years - 70 Years | Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias | |
| A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations | NCT01657682 | Acute Myeloid L... | Crenolanib besy... | 18 Years - | Arog Pharmaceuticals, Inc. | |
| In Vitro Drug Sensitivity Testing of Fresh Human Samples | NCT05001386 | Myeloproliferat... Lymphoprolifera... | Blood collectio... | 18 Years - | Hospices Civils de Lyon | |
| Mismatched Donor Cells to Treat Acute Myeloid Leukemia | NCT01793025 | Acute Myeloid L... | ATAC Therapy | 18 Years - | Maisonneuve-Rosemont Hospital | |
| Pre-Transplant 5-Azacitidine In Patients With High-Risk Myelodysplastic Syndrome Who Are Candidates For Allogeneic Hematopoietic Cell Transplant | NCT00660400 | Leukemia | 5-azacitidine Allogeneic Hema... | 18 Years - 68 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML) | NCT00989261 | Acute Myeloid L... | Compound AC220 | 18 Years - 85 Years | Daiichi Sankyo | |
| A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms | NCT04955938 | IDH Mutation IDH1 Mutation IDH2 Gene Mutat... Blood Cancer Myeloproliferat... | Ivosidenib Enasidenib Fedratinib | 18 Years - | University of Chicago | |
| Maintenance Azacitidine in Elderly Patients With Acute Myeloid Leukemia (AML) in CR After Induction Chemotherapy | NCT00387647 | Leukemia | Azacitidine | 60 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms | NCT00665002 | Leukemia | WT-1 Montanide Sargramostim (G... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome. | NCT01236144 | Acute Myeloid L... High Risk Myelo... | Plerixafor AC220 Ganetespib | 60 Years - | Cardiff University | |
| Comparing Two Diets in Patients Undergoing HSCT or Remission Induction Chemo for Acute Leukemia and MDS (UF-BMT-LDND-101) | NCT03016130 | Leukemia Myelodysplastic... | Diet | 18 Years - | University of Florida | |
| A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations | NCT02381886 | Advanced Malign... | IDH305 | 18 Years - | Novartis | |
| Risk-adapted Therapy for Primary Acute Myeloid Leukemia | NCT04687098 | Leukemia, Myelo... | Idarubicin Ara-C G-CSF Allogeneic matc... Autologous peri... Measurable resi... | 17 Years - 70 Years | Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias | |
| Study Protocol: Study on Incidence and Risk Factors of Mold Infections in Children During Leukemia Treatment | NCT05774990 | Leukemia, Myelo... Acute Lymphobla... | - 17 Years | University of Southern Denmark | ||
| A Clinical Research of CD123-Targeted CAR-T in Myeloid Malignancies | NCT02937103 | Leukemia | Anti-CD123-CAR-... | 14 Years - 75 Years | Southwest Hospital, China | |
| Mismatched Donor Cells to Treat Acute Myeloid Leukemia | NCT01793025 | Acute Myeloid L... | ATAC Therapy | 18 Years - | Maisonneuve-Rosemont Hospital | |
| Safety, Pharmacokinetics and Pharmacodynamics of TKI258 in Subjects With Acute Myeloid Leukemia | NCT00279773 | Acute Myeloid L... | TKI258 | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
